GLP-1 based therapies and disease course of inflammatory bowel disease

GLP-1 based therapies and disease course of inflammatory bowel disease

Background: The disease course of inflammatory bowel disease (IBD) following treatment with glucagon-like peptide (GLP)-1 based therapies is unclear. The aim of this study was to examine the disease course of IBD in patients treated with GLP-1 based therapies compared with treatment with other antid...

Full description

Bibliographic Details
Main Authors: Marie Villumsen, Astrid Blicher Schelde, Espen Jimenez-Solem, Tine Jess, Kristine Højgaard Allin
Format: Article
Language:English
Published: Elsevier 2021-07-01
Series:EClinicalMedicine
Subjects:
Colitis ulcerative
Crohn's disease
Glucagon-like-peptide 1 receptor agonists
Dipeptidyl peptidase-4 inhibitors
Pharmacoepidemiology
Prognosis
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537021002595

Internet

http://www.sciencedirect.com/science/article/pii/S2589537021002595

Similar Items